---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-050592"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2021-09-29T23:59:59+00:00"
generated_at: "2026-06-29T00:45:38.729334+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Amplitude Healthcare completes business combination with Jasper Therapeutics; begins trading as JSPR

## Summary
- Redemption of 9,262,099 AMHC shares for $92.7M; PIPE of $100M from 10M shares at $10.00 each.
- Old Jasper equity valued at $275M; post-closing shares: 36.5M voting, 1.3M non-voting, 2.7M options.
- Sponsor deposited 1,050,000 earnout shares subject to price thresholds of $11.50, $15, $18 VWAP.
- New company renamed Jasper Therapeutics, Inc.; tickers JSPR (common) and JSPRW (warrants) on Nasdaq.
- Amended registration rights agreement with 180-day lock-up; indemnification agreements with directors/officers.

## SEC filing metadata
- accession: 0001213900-21-050592
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2021-09-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 9.01, 5.02, 3.02, 4.01, 5.01, 5.06, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/ea147929-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-050592
- JSON: https://secwatch.observer/filing/0001213900-21-050592.json
- Plain text: https://secwatch.observer/filing/0001213900-21-050592.txt

## Key facts
- Executive change
  Vishal Kapoor departed as Executive Officer at Jasper Therapeutics, Inc..
  - Action: ceased serving
  - Role: Executive Officer
  source text: each of Bala Venkataraman, Kenneth Clifford and Vishal Kapoor ceased serving as an executive officer of AMHC.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm
- Executive change
  Bala Venkataraman departed as Executive Officer at Jasper Therapeutics, Inc..
  - Action: ceased serving
  - Role: Executive Officer
  source text: each of Bala Venkataraman, Kenneth Clifford and Vishal Kapoor ceased serving as an executive officer of AMHC.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm
- Executive change
  Kenneth Clifford departed as Executive Officer at Jasper Therapeutics, Inc..
  - Action: ceased serving
  - Role: Executive Officer
  source text: each of Bala Venkataraman, Kenneth Clifford and Vishal Kapoor ceased serving as an executive officer of AMHC.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm
- Executive change
  William Lis was appointed as President, Chief Executive Officer and Executive Chairman at Jasper Therapeutics, Inc..
  - Action: appointed
  - Role: President, Chief Executive Officer and Executive Chairman
  source text: William Lis President, Chief Executive Officer and Executive Chairman of the New Jasper Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm
- Executive change
  Kevin N. Heller, M.D. was appointed as Executive Vice President, Research and Development at Jasper Therapeutics, Inc..
  - Action: appointed
  - Role: Executive Vice President, Research and Development
  source text: Kevin N. Heller, M.D. Executive Vice President, Research and Development
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm
- Executive change
  Jeet Mahal was appointed as Chief Financial and Business Officer and Corporate Secretary at Jasper Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial and Business Officer and Corporate Secretary
  source text: Jeet Mahal Chief Financial and Business Officer and Corporate Secretary
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.